Viking Therapeutics' VK2735 Shows Promising Weight Loss and Market Potential in Obesity Treatment

Viking Therapeutics' phase 1 trial of VK2735 revealed significant weight loss results, positioning it as a strong contender in the obesity treatment market. In a study involving 27 participants, the highest 100 mg oral dose achieved an average weight loss of 8.2% over 28 days, which is a remarkable outcome compared to placebo[1][3]. This efficacy surpasses that of other oral obesity drugs and places VK2735 ahead of competitors like Structure Therapeutics' GSBR-1290, which showed lower weight loss rates over a similar period[3]. Furthermore, VK2735 demonstrated a favorable safety profile, with most adverse events being mild or moderate, increasing the drug's appeal as it moves towards further clinical trials [2].